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Adenylate kinases (AKs) are phosphotransferase enzymes that catalyze the
interconversion of adenine nucleotides, thereby playing an important role in
energy metabolism. In Plasmodium falciparum, three AK isoforms, namely
PfAK1, PfAK2 and GTP:AMP phosphotransferase (PfGAK), have been
identified. While PfAK1 and PfAK2 catalyse the conversion of ATP and AMP
to two molecules of ADP, PfGAK exhibits a substrate preference for GTP and
AMP and does not accept ATP as a substrate. PfGAKwas cloned and expressed
in Escherichia coli and purified using two-step chromatography. Brown
hexagonal crystals of PfGAK were obtained and a preliminary diffraction
analysis was performed. X-ray diffraction data for a single PfGAK crystal were
processed to 2.9 A˚ resolution in space group P3121 or P3221, with unit-cell
parameters a = b = 123.49, c = 180.82 A˚,  =  = 90,  = 120.
1. Introduction
Malaria is a parasitic infectious disease that is widespread in tropical
and subtropical regions and affects 350–500 million people a year
(Wells & Poll, 2010; Hay et al., 2004). Amongst the five Plasmodium
species that account for human infections (P. falciparum, P. vivax,
P. malariae, P. ovale and P. knowlesi), P. falciparum is the most
virulent (World Health Organization, 2009; Sinclair et al., 2009). With
the increasing drug resistance of the parasite and no vaccine in sight,
new chemotherapeutic approaches are required (Petersen et al.,
2011).
Adenylate kinases (AKs) are cell energy regulators that play
important roles in complex phosphotransfer networks that control
intracellular ATP-production processes (Dzeja et al., 2002; Dzeja &
Terzic, 2003). In many organisms these enzymes participate in a
variety of physiological functions, such as muscle contraction and cell
motility (Hancock et al., 2006; Cao et al., 2006). The malaria parasite
Plasmodium has a high rate of ATP turnover, as merozoite invasion
involves high-performance ATP-dependent actomyosin motors and
the mature parasite has to supply the host erythrocytes with ATP
(Webster & Whaun, 1981). These processes require AKs, making
them attractive antimalarial targets.
AKs belong to the nucleotide monophosphate (NMP) kinase
superfamily. They exhibit a typical / protein fold consisting of a
CORE ATP-binding domain with a central five-stranded -sheet
surrounded by -helices, a smaller NMP-binding domain composed
of three -helices and a LID domain of flexible residues covering the
phosphate-donor site (Yan & Tsai, 1999). There are two forms of
AKs, the short form and the long form, which differ by a 20–30
amino-acid-residue insertion in the LID domain (Mu¨ller & Schulz,
1992). Mammalian AKs are short AKs, while those from bacteria,
yeast and mitochondria are long AKs. Different oligomeric forms are
observed for AKs: eubacterial AKs are monomeric, while archae-
bacterial AKs exist in a trimeric form (Vonrhein et al., 1998). In
addition, dimeric forms of AK have also been reported (Perrier et al.,
1998).
Three isoforms of AK have been identified in P. falciparum, all of
which belong to the long form. Of these isoforms of P. falciparum
AK, PfAK1 and PfAK2 specifically bind AMP and favour ATP over
other nucleotide triphosphates, whereas GTP:AMP phosphotrans-
# 2012 International Union of Crystallography
All rights reserved
ferase (PfGAK) exhibits a substrate preference for GTP and AMP
(Ulschmid et al., 2004). PfGAK corresponds to mammalian AK3 and
shares 25% sequence identity with human AK3. While human AK3
accepts both GTP and ATP as phosphate donors, PfGAK specifically
utilizes only GTP for phosphate transfer (Ulschmid et al., 2004). In
addition, it has been shown that the nucleotide analogue GP5A
strongly inhibits PfGAK activity (Ulschmid et al., 2004); this makes
GP5A an attractive lead compound to assist in the design of drugs
that are specific against this enzyme. Here, we report the expression,
purification and crystallization of PfGAK and a preliminary X-ray
diffraction analysis.
2. Methods and materials
2.1. Expression and purification
The coding region for PfGAK (Gene ID PFD0755c) was amplified
using PCR from genomic DNA of P. falciparum strain 3D7 and was
inserted into the bacterial expression vector pET28b (Novagen) via
NdeI and XhoI restriction sites. The resultant plasmid encodes
PfGAK with an N-terminal 6His tag with the sequence MGSH-
HHHHSSGLVPAGSH–. The PfGAK plasmid was transformed into
Escherichia coli BL21 (DE3) Rosetta 2 cells (Novagen). The trans-
formed cells were grown in 2TY medium containing 30 mg ml1
kanamycin and 30 mg ml1 chloramphenicol at 310 K with shaking
at 225 rev min1 until the OD600 of the cells reached 0.8. Protein
expression was induced with 0.5 mM isopropyl -d-1-thiogalacto-
pyranoside (IPTG) and the cells were incubated for a further 16–18 h
at 289 K.
The cells were harvested, resuspended in lysis buffer (25 mM Tris–
HCl pH 8.5, 50 mM NaCl, 20 mM imidazole, 0.1 mM PMSF) and
lysed by sonication. After centrifugation at 12 000g for 45 min at
277 K, the cleared lysate was loaded onto a 5 ml HisTrap column (GE
Healthcare) pre-equilibrated with lysis buffer. Recombinant PfGAK
was eluted with a linear gradient of 20–250 mM imidazole in lysis
buffer. Fractions containing PfGAK were pooled and concentrated.
The concentrated PfGAK protein was loaded onto a Superdex 200
16/60 size-exclusion column (GE Healthcare) pre-equilibrated with
25 mM Tris–HCl pH 8.5, 40 mM KCl, 2 mM DTT, from which it
eluted as a dimer. In each purification step, fractions containing the
protein were analyzed by 12% SDS–PAGE and appropriate fractions
were pooled. After size-exclusion chromatography, fractions
containing PfGAK were pooled and concentrated using Amicon
Ultra centrifugal concentrators (10 kDa cutoff, Millipore). The
concentration of PfGAK was determined spectrophotometrically at
280 nm with a NanoVue Plus (GE Healthcare) using its theoretical
extinction coefficient of 12 170.
2.2. Crystallization
Screening of crystallization conditions was performed by a
Mosquito liquid handler (TTP LabTech) at 291 K using the sitting-
drop vapour-diffusion method, mixing 200 nl PfGAK at 12 mg ml1
with an equal volume of crystallization solution. Of the 576 condi-
tions screened, initial hits were observed in Index (Hampton
Research) condition No. 4 (2.0M ammonium sulfate, 0.1M bis-Tris–
HCl pH 6.5) and Protein Complex Suite (Qiagen) condition No. 76
(2.0M ammonium sulfate, 0.1M Tris–HCl pH 8.0). After optimiza-
tion, improved crystals of PfGAK were grown in 1.9–2.1M ammo-
nium sulfate, 0.1M Tris–HCl pH 8.0 by mixing 2 ml PfGAK solution
with 2 ml well solution.
2.3. Data collection and processing
PfGAK crystals were soaked in a cryobuffer consisting of 4M
ammonium sulfate, 0.1M Tris–HCl pH 8.0 for about 5 min and flash-
cooled by immersion in liquid nitrogen. Data collection was carried
out on beamline 13B1, National Synchrotron Radiation Research
Center (NSRRC), Hsinchu, Taiwan. Data collection from a single
PfGAK crystal was performed with an exposure of 20 s per frame (1
oscillation) and at a wavelength of 1 A˚. A total of 90 frames were
collected using an ADSC Quantum 315 CCD detector. Diffraction
intensities were integrated and scaled using HKL-2000 (Otwinowski
& Minor, 1997).
3. Results and discussion
The DNA segment encoding PfGAK was cloned into the pET28b
expression vector, resulting in the addition of an N-terminal 6His
tag. Recombinant PfGAK was expressed in E. coli BL21 (DE3)
Rosetta 2 cells (Novagen) and purified (Fig. 1). Crystals of PfGAK
appeared after one week of incubation in the initial crystallization
screen at 291 K. After optimization, single hexagonal crystals of
PfGAKwhich were brown in colour grew to maximum dimensions of
0.3  0.1  0.1 mm over a period of 3–5 d (Fig. 2).
X-ray diffraction and data collection of PfGAK crystals were
performed on beamline 13B1 at NSRRC, Taiwan. A complete data
set was collected from a single crystal to 2.9 A˚ resolution (Fig. 3) and
was processed in space group P321 without a screw component.
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Figure 1
12% SDS–PAGE analysis of PfGAK purified by size-exclusion chromatography.
Lane M, molecular-weight marker (labelled in kDa); lane 1, semi-purified PfGAK
before size-exclusion chromatography; lanes 5–13, fractions of purified PfGAK
following size-exclusion chromatography.
Figure 2
Crystal of PfGAK. Crystals typically grew to maximum dimensions of 0.3  0.1 
0.1 mm.
Systematic absences were then used to determine the exact space
group as eitherP3121orP3221,with unit-cell parameters a=b=123.49,
c = 180.82 A˚,  =  = 90,  = 120. Despite PfGAK being a dimer in
solution, the asymmetric unit was estimated to contain four to seven
copies of PfGAK, with the crystal volume per unit molecular weight,
VM, calculated to be between 2.10 and 3.68 A˚
3 Da1, corresponding
to a solvent content of 41.6–66.6% (Matthews, 1968). Attempts to
detect the self-rotation function of PfGAK in the asymmetric unit
using POLARRFN and MOLREP from the CCP4 suite (Winn et al.,
2011) were inconclusive. As PfGAK exists as a dimer in solution, we
predict that the asymmetric unit of the crystal should contain four to
six copies of PfGAK, corresponding to two to three dimers. The data-
collection statistics are summarized in Table 1.
The solution of the structure of PfGAK is currently being actively
pursued by the use of both heavy-atom derivatization and seleno-
methionine incorporation of the protein for MIR and MAD/SAD
phasing, respectively, as molecular replacement using homologous
proteins such as the AKs from E. coli (PDB entry 1ake; 31%
homology; Mu¨ller & Schulz, 1992), Saccharomyces cerevisiae (PDB
entry 3aky; 33% homology; Spuergin et al., 1995) and Bacillus subtilus
(PDB entry 2osb; 32% homology; R. Counago, C. J. Wilson, J. Myers,
G. Wu, Y. Shamoo & P. Wittung-Stafshede, unpublished work) was
unsuccessful.
We would like to thank the staff at beamline 13B1 of the National
Synchrotron Radiation Research Centre, Taiwan for their support
and assistance. AWLL was supported by a postgraduate studentship
from the HKU SPACE Research Fund.
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Crystallographic data-collection statistics for PfGAK.
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Diffraction image of the PfGAK crystal collected at NSRRC, Taiwan. The resolution limit at the edge is 2.9 A˚. The insert shows a enlarged view of the diffraction at the edge
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